Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/10/22
Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022GlobeNewsWire • 03/10/22
Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear MarketSeeking Alpha • 03/08/22
Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 MillionGlobeNewsWire • 01/07/22
Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman LitigationGlobeNewsWire • 12/29/21
FDA Grants Tentative Approval for Liquidia's YUTREPIA™ (Treprostinil) Inhalation PowderGlobeNewsWire • 11/08/21
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/21
Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/03/21
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/10/21
FDA Completes On-site Pre-Approval Inspection of Liquidia's Morrisville, North Carolina FacilityGlobeNewsWire • 08/18/21
Liquidia Corporation's (LQDA) CEO Damian deGoa on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/21
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation PowderGlobeNewsWire • 06/02/21
Liquidia Corporation To Present At The Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/21